CHR Hansen Holding - 2018, November 29
In general, Chr. Hansen is in compliance with the Danish regulations relating to the organisation and procedures of the Annual General Meeting.
In April 2018, Chr. Hansen presented an updated corporate strategy for the period until 2022. The name is still Nature's no. 1, but now with the subtitle 'Sustainably'. The strategic pillars remain the same and the Company's financial ambitions were also updated.
On an organisational level, Mr. Mauricio Graber has been appointed as the new CEO of Chr. Hansen as of June 1, 2018 and thereby succeeded Mr. Cees de Jong, who decided to pursue a career as non-executive director outside the Company.
Under ITEM 6b (1) it is proposed to re-appoint Mr. Jesper Brandgaard as Member of the board of directors. ECGS has concerns over his aggregate time commitments. Mr. Brandgaard is serving as EVP Biopharm and Legal Affairs of Novo Nordisk A/S (listed), Chairman of the board of directors of Simcorp A/S (listed) and non-executive director of Chr. Hansen Holding A/S (listed), which exceeds ECGS' guidelines. Therefore, ECGS normally would have recommended opposition. However, considering that the proxy card does not permit this, it recommends abstention instead.
There are no further peculiarities.
Chr. Hansen is a biosciences group based in Denmark. Co. develops and supplies natural ingredient solutions for the food, pharmaceutical, nutritional, and agricultural industries worldwide. Co. operates in three divisions: Cultures and Enzymes (develops, produces, and sells cultures, enzymes, and probiotics for the food and dairy industries); Health and Nutrition (develops products for the dietary supplement, over-the-counter pharmaceutical, infant formula, and animal feed industries); and Natural Colors (develops natural color solutions to the food industry, primarily for the beverage, dairy, confectionery, fruit preparation and ice cream, as well as functional blends for processed meats).
Founded in 1995, Proxinvest is an independent proxy firm supporting the engagement and proxy analysis processes of investors. Proxinvest mission is to analyse corporate governance practices and resolutions proposed at general meetings of listed firms.
Proxinvest main services are :
- Proxy reports
- Definition and monitoring of client customized voting guidelines
- Corporate Governance Data and Rating
- Thematic research
- Engagement support
Proxinvest has been a pioneer and champion of good corporate governance and has grown into a recognised expert in the field.
Proxinvest is independently-owned and only works for investors : Proxinvest does not provide consulting services to the companies it covers, mitigating related risks to its clients and ensuring the independence of our analysis. As a result Proxinvest is able to take a robust, independent, engaged and unconflicted view of the companies in which our clients invest.
As Managing Partner of Expert Corprate Governance Service Ltd (ECGS), Proxinvest has built a large network of corporate governance experts to support clients in corporate governance analysis worldwide.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.